Can infection-related antibodies cross-react with neural proteins without proving brain autoimmunity?

Infections can precipitate immune responses relevant to neurologic disease, but the presence of neural-reactive antibodies—especially in serum—must be separated from proof of active pathogenic brain autoimmunity.

Clinical and diagnostic evidence

• Serum neural-antibody positivity alone has limited specificity. In a large cohort, only 31% of serum-only positive patients had probable or definite autoimmune neurologic disease, compared with 91% of CSF-only positive patients.
• Clinically irrelevant serum-only results have occurred for GAD65, NMDAR, Yo, GABA-B receptor, and CV2 antibodies. A positive result can therefore be incidental, assay-related, or incompatible with the patient’s neurologic phenotype.
• Autoimmune encephalitis requires a compatible subacute syndrome plus objective CNS evidence—such as seizures, focal deficits, CSF pleocytosis, suggestive MRI, or EEG abnormalities—and reasonable exclusion of alternatives. Paired CSF/serum testing and orthogonal confirmation are particularly important for serum-positive/CSF-negative or phenotype-discordant results.

Mechanisms

• Molecular mimicry has strong precedent in defined post-infectious disorders. Campylobacter jejuni lipooligosaccharides can mimic gangliosides (GM1, GD1a, GQ1b), inducing antibodies linked to complement-mediated peripheral-nerve injury in Guillain–Barré syndrome.
• In Sydenham chorea, antibodies recognizing streptococcal and neuronal targets have shown functional effects, including neuronal CaMKII activation and increased dopamine release.
• Bystander inflammation is a credible amplifier: cytokine/innate signaling can activate autoreactive lymphocytes; tissue injury releases antigens and promotes epitope spreading; inflammation can impair blood–brain-barrier integrity, increasing neural access of antibodies and immune cells. Direct human proof that this mechanism alone generates a specific neural cross-reactive antibody remains limited.

Bottom line

• Infection-related molecular mimicry can generate neural cross-reactive antibodies, while inflammation may broaden and facilitate autoimmunity. A serum neural antibody is a diagnostic clue—not proof of pathogenic brain autoimmunity—and requires clinical, CSF, imaging/EEG, and assay-context concordance.